<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012957</url>
  </required_header>
  <id_info>
    <org_study_id>DESI.18.001</org_study_id>
    <nct_id>NCT04012957</nct_id>
  </id_info>
  <brief_title>Desidustat in the Treatment of Anemia in CKD</brief_title>
  <acronym>DREAM-ND</acronym>
  <official_title>A Phase 3, Multicenter, Multi-country, Open-label, Randomized, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Desidustat Versus Darbepoetin for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) Who Are Not on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled&#xD;
      clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the&#xD;
      treatment of anemia in patients with CKD who are not on dialysis. The study will be conducted&#xD;
      over a period of up to 30 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 20, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 23, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Hb levels from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>No. of subjects with Hb response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin target range</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to achieve target range Hb level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">588</enrollment>
  <condition>Chronic Kidney Disease Stage 3</condition>
  <condition>Anemia</condition>
  <condition>Chronic Kidney Disease Stage 4</condition>
  <condition>Chronic Kidney Disease Stage 5</condition>
  <arm_group>
    <arm_group_label>Darbepoetin Alfa Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomly assigned to receive Darbepoetin in a 1:1 ratio for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desidustat oral tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desidustat Oral Tablet</intervention_name>
    <description>Desidustat tablet</description>
    <arm_group_label>Desidustat oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin Alfa</intervention_name>
    <description>Darbepoetin injection</description>
    <arm_group_label>Darbepoetin Alfa Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Current clinical diagnosis of anemia due to CKD, baseline hemoglobin concentrations&#xD;
             must be 7.0-10.0 g/dL (both inclusive) before the enrollment.&#xD;
&#xD;
          2. Ability to understand and give informed consent for participation.&#xD;
&#xD;
          3. Male or female patients diagnosed with CKD (stage III to V, not receiving dialysis)&#xD;
             defined by estimated glomerular filtration rate (eGFR) using the CKD Epidemiology&#xD;
             Collaboration (CKD-EPI) formula.&#xD;
&#xD;
          4. Male or female, 18 to 80 years of age.&#xD;
&#xD;
          5. Body weight &gt; 40 kg.&#xD;
&#xD;
          6. Subjects not on dialysis and not expected to start dialysis during the study period.&#xD;
&#xD;
          7. Patients must not be treated with erythropoiesis-stimulating agent (ESA) therapy&#xD;
             within 6 weeks prior to enrollment.&#xD;
&#xD;
          8. Estimated GFR ≥10 mL/min/1.73 m2.&#xD;
&#xD;
          9. Serum ferritin ≥100 ng/mL and/or Transferrin Saturation &gt;20%.&#xD;
&#xD;
         10. No iron, folate or Vitamin B12 deficiency.&#xD;
&#xD;
         11. Females of childbearing potential, must agree to use one of the approved contraception&#xD;
             methods, from screening until completion of the follow-up visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chronic hemodialysis or chronic peritoneal dialysis treatment.&#xD;
&#xD;
          2. Intravenous iron within 14 days prior to enrollment.&#xD;
&#xD;
          3. Prior exposure of rhEPO analogues less than 04 weeks.&#xD;
&#xD;
          4. Red blood cell transfusion within 8 weeks prior to enrollment.&#xD;
&#xD;
          5. History of previous or concurrent cancer.&#xD;
&#xD;
          6. Serologic status reflecting active hepatitis B or C infection or Human&#xD;
             immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          7. Active infection prior to enrollment.&#xD;
&#xD;
          8. History of renal transplant.&#xD;
&#xD;
          9. Major surgery within 90 days of the first day of study drug dosing, and minor surgery&#xD;
             within 30 days of the first day of study drug dosing.&#xD;
&#xD;
         10. Unable to swallow tablets or disease significantly affecting gastrointestinal function&#xD;
             and/or inhibiting small intestine absorption such as; mal-absorption syndrome,&#xD;
             resection of the small bowel or poorly controlled inflammatory bowel disease affecting&#xD;
             the small intestine.&#xD;
&#xD;
         11. History of uncontrolled autoimmune hemolytic anemia, idiopathic thrombocytopenic&#xD;
             purpura (ITP) or thalassemia.&#xD;
&#xD;
         12. Presence or a history of bleeding disorders or clinical conditions (e.g.&#xD;
             gastrointestinal [GI] bleeding or constitutional disorders) that may increase risk of&#xD;
             life-threatening bleeding.&#xD;
&#xD;
         13. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.&#xD;
&#xD;
         14. History of severe allergic or hypersensitivity to investigational products and its&#xD;
             excipients.&#xD;
&#xD;
         15. Requires or is receiving anticoagulation with warfarin or equivalent vitamin K&#xD;
             antagonists or other medications within 28 days of the first dose of study drug that&#xD;
             in the investigator's opinion, could compromise patient safety.&#xD;
&#xD;
         16. Pregnant and breastfeeding women.&#xD;
&#xD;
         17. Current life-threatening illness, medical condition or organ system dysfunction which,&#xD;
             in the Investigator's opinion, could compromise the patient's safety.&#xD;
&#xD;
         18. Other laboratory abnormalities that, in the opinion of the investigator, would&#xD;
             compromise the patient's safety or interfere with data interpretation.&#xD;
&#xD;
         19. Presence of other systemic disorders or diseases (e.g., respiratory, gastrointestinal,&#xD;
             endocrine, immunological, dermatological, neurological, psychiatric disease or any&#xD;
             other body system involvement) which, in the Investigator's opinion, could compromise&#xD;
             the patient's safety.&#xD;
&#xD;
         20. History of significant alcoholism or drug abuse within the past 1 year. History or&#xD;
             presence of significant smoking (more than 10 cigarettes per day) or consumption of&#xD;
             tobacco/nicotine products (more than 10 times per day).&#xD;
&#xD;
         21. History of difficulty with donating blood.&#xD;
&#xD;
         22. History or presence of any clinically significant ECG abnormalities during screening.&#xD;
&#xD;
         23. Participants who have participated in any drug research study other than the present&#xD;
             trial within past 3 months.&#xD;
&#xD;
         24. Participants who have donated one unit (350 ml) of blood in the past 3 months or&#xD;
             history of whole blood transfusion in last 120 days prior to enrollment.&#xD;
&#xD;
         25. History of chronic inflammatory disease (RA, Celiac disease, UC, Crohns disease,&#xD;
             Systemic Lupus Erythematosus [SLE]).&#xD;
&#xD;
         26. In case of Diabetes mellitus patients, glycosylated haemoglobin (HbA1c) &gt;9 %.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DrDeven Parmar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cadila Healthcare Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunrise Hospital</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Super Specialty Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thakershey Charitable trust Hospital</name>
      <address>
        <city>Ahmadabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCG Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sangini Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSC Medical College and Research Centre</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAPS Pramukh Swami Hospital</name>
      <address>
        <city>Sūrat</city>
        <state>Gujarat</state>
        <zip>395009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dhiraj General Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapthagiri Institute of Medical Sciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560090</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Science</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Government Medical College</name>
      <address>
        <city>Kozhikode</city>
        <state>Kerala</state>
        <zip>673008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahatma Gandhi Mission Medical College &amp; Hospital</name>
      <address>
        <city>Aurangabad</city>
        <state>Maharashtra</state>
        <zip>431003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nav Sanjeevani Hospital (Sankalp Speciality Healthcare Pvt. Ltd)</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhaktivedanta Hospital and Research Institute</name>
      <address>
        <city>Thāne</city>
        <state>Maharashtra</state>
        <zip>401107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Institute Of Medical Sciences (AIMS) Hospital</name>
      <address>
        <city>Thāne</city>
        <state>Maharashtra</state>
        <zip>421203</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Hospital</name>
      <address>
        <city>Delhi</city>
        <state>New Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sardar Patel Medical College</name>
      <address>
        <city>Bīkaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sawai Man Singh (SMS) Medical College and Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eternal Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rukmani Birla Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osmania General Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500058</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizams Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizams Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>524001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Hospitals Limited</name>
      <address>
        <city>Varanasi</city>
        <state>Uttar Pradesh</state>
        <zip>221311</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shri Mahant Indiresh Hospital</name>
      <address>
        <city>Dehradun</city>
        <state>Uttaranchal</state>
        <zip>248001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Superspecialty Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bangal</state>
        <zip>700099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peerless Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>WEST Bengal</state>
        <zip>700094</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DREAM-ND</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

